Cargando…

Adoptive Transfer of Anti-Nucleolin T Cells Combined with PD-L1 Inhibition against Triple-Negative Breast Cancer

Dendritic cell (DC)–based T-cell activation is an alternative immunotherapy in breast cancer. The anti-programmed death ligand 1 (PD-L1) can enhance T-cell function. Nucleolin (NCL) is overexpressed in triple-negative breast cancer (TNBC). The regulation of PD-L1 expression through autophagy and the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Thongchot, Suyanee, Jirapongwattana, Niphat, Luangwattananun, Piriya, Chiraphapphaiboon, Wannasiri, Chuangchot, Nisa, Sa-nguanraksa, Doonyapat, O-Charoenrat, Pornchai, Thuwajit, Peti, Yenchitsomanus, Pa-thai, Thuwajit, Chanitra
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Association for Cancer Research 2022
Materias:	Small Molecule Therapeutics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9377762/ https://www.ncbi.nlm.nih.gov/pubmed/35313339 http://dx.doi.org/10.1158/1535-7163.MCT-21-0823

Ejemplares similares

Mesothelin-specific T cell cytotoxicity against triple negative breast cancer is enhanced by 40s ribosomal protein subunit 3-treated self-differentiated dendritic cells
por: Jirapongwattana, Niphat, et al.
Publicado: (2022)

Enhancement of PD-L1-attenuated CAR-T cell function through breast cancer-associated fibroblasts-derived IL-6 signaling via STAT3/AKT pathways
por: Chuangchot, Nisa, et al.
Publicado: (2023)

Breast cancer stem cell RNA-pulsed dendritic cells enhance tumor cell killing by effector T cells
por: Sumransub, Nuttavut, et al.
Publicado: (2020)

Nucleolin-based targeting strategies in cancer treatment: Focus on cancer immunotherapy (Review)
por: Thongchot, Suyanee, et al.
Publicado: (2023)

Activation of cytotoxic T lymphocytes by self-differentiated myeloid-derived dendritic cells for killing breast cancer cells expressing folate receptor alpha protein
por: Luangwattananun, Piriya, et al.
Publicado: (2022)

Establishment and characterization of novel highly aggressive HER2-positive and triple-negative breast cancer cell lines
por: Thongchot, Suyanee, et al.
Publicado: (2021)

Cellular localization of nucleolin determines the prognosis in cancers: a meta-analysis
por: Yangngam, Supaporn, et al.
Publicado: (2022)

Development of an engineered peptide antagonist against periostin to overcome doxorubicin resistance in breast cancer
por: Oo, Khine Kyaw, et al.
Publicado: (2021)

Periostin regulates autophagy through integrin α5β1 or α6β4 and an AKT‐dependent pathway in colorectal cancer cell migration
por: Thongchot, Suyanee, et al.
Publicado: (2020)

Cancer-associated fibroblasts induce high mobility group box 1 and contribute to resistance to doxorubicin in breast cancer cells
por: Amornsupak, Kamolporn, et al.
Publicado: (2014)

Interleukin-8 released by cancer-associated fibroblasts attenuates the autophagy and promotes the migration of ovarian cancer cells
por: Thongchot, Suyanee, et al.
Publicado: (2021)

HMGB1 mediates invasion and PD-L1 expression through RAGE-PI3K/AKT signaling pathway in MDA-MB-231 breast cancer cells
por: Amornsupak, Kamolporn, et al.
Publicado: (2022)

Periostin induces epithelial-to-mesenchymal transition via the integrin α5β1/TWIST-2 axis in cholangiocarcinoma
por: Sonongbua, Jumaporn, et al.
Publicado: (2020)

Novel CSF1R-positive tenosynovial giant cell tumor cell lines and their pexidartinib (PLX3397) and sotuletinib (BLZ945)-induced apoptosis
por: Thongchot, Suyanee, et al.
Publicado: (2022)

High level of interleukin-33 in cancer cells and cancer-associated fibroblasts correlates with good prognosis and suppressed migration in cholangiocarcinoma
por: Yangngam, Supaporn, et al.
Publicado: (2020)

Compound A attenuates toll-like receptor 4-mediated paclitaxel resistance in breast cancer and melanoma through suppression of IL-8
por: Sootichote, Rochanawan, et al.
Publicado: (2018)

The Role of Vascular Endothelial Growth Factor A Polymorphisms in Breast Cancer
por: Sa-nguanraksa, Doonyapat, et al.
Publicado: (2012)

Increased ETV4 expression correlates with estrogen-enhanced proliferation and invasiveness of cholangiocarcinoma cells
por: Singsuksawat, Ekapot, et al.
Publicado: (2018)

Itraconazole Exerts Its Antitumor Effect in Esophageal Cancer By Suppressing the HER2/AKT Signaling Pathway
por: Zhang, Wei, et al.
Publicado: (2021)

The metabolic cross‐talk between epithelial cancer cells and stromal fibroblasts in ovarian cancer progression: Autophagy plays a role
por: Thuwajit, Chanitra, et al.
Publicado: (2017)

Clinical Positioning of the IAP Antagonist Tolinapant (ASTX660) in Colorectal Cancer
por: Crawford, Nyree, et al.
Publicado: (2021)

DNAPK Inhibition Preferentially Compromises the Repair of Radiation-induced DNA Double-strand Breaks in Chronically Hypoxic Tumor Cells in Xenograft Models
por: Jiang, Yanyan, et al.
Publicado: (2021)

PARP and CDK4/6 Inhibitor Combination Therapy Induces Apoptosis and Suppresses Neuroendocrine Differentiation in Prostate Cancer
por: Wu, Cheng, et al.
Publicado: (2021)

T Cell–Mediated Antitumor Immunity Cooperatively Induced By TGFβR1 Antagonism and Gemcitabine Counteracts Reformation of the Stromal Barrier in Pancreatic Cancer
por: Li, Dandan, et al.
Publicado: (2021)

ONC212 is a Novel Mitocan Acting Synergistically with Glycolysis Inhibition in Pancreatic Cancer
por: Ferrarini, Isacco, et al.
Publicado: (2021)

VLX600 Disrupts Homologous Recombination and Synergizes with PARP Inhibitors and Cisplatin by Inhibiting Histone Lysine Demethylases
por: Ekstrom, Thomas L., et al.
Publicado: (2021)

Evaluation of the Small-molecule BRD4 Degrader CFT-2718 in Small-cell Lung Cancer and Pancreatic Cancer Models
por: Sun, Danlin, et al.
Publicado: (2021)

Cyclin-dependent Kinase 4/6 Inhibitor Palbociclib in Combination with Ralaniten Analogs for the Treatment of Androgen Receptor–positive Prostate and Breast Cancers
por: Tien, Amy H., et al.
Publicado: (2022)

Radiopotentiation Profiling of Multiple Inhibitors of the DNA Damage Response for Early Clinical Development
por: Gill, Sonja J., et al.
Publicado: (2021)

Gilteritinib Inhibits Glutamine Uptake and Utilization in FLT3-ITD–Positive AML
por: Zavorka Thomas, Megan E., et al.
Publicado: (2021)

Protein Phosphatase 2A as a Therapeutic Target in Small Cell Lung Cancer
por: Mirzapoiazova, Tamara, et al.
Publicado: (2021)

Triple Targeting of Breast Tumors Driven by Hormonal Receptors and HER2
por: Shagisultanova, Elena, et al.
Publicado: (2022)

Targeting the T-Cell Lymphoma Epigenome Induces Cell Death, Cancer Testes Antigens, Immune-Modulatory Signaling Pathways
por: Scotto, Luigi, et al.
Publicado: (2021)

Comprehensive Surfaceome Profiling to Identify and Validate Novel Cell-Surface Targets in Osteosarcoma
por: Wang, Yifei, et al.
Publicado: (2022)

Silylation of Deoxynucleotide Analog Yields an Orally Available Drug with Antileukemia Effects
por: Ureshino, Hiroshi, et al.
Publicado: (2021)

Preclinical and Early Clinical Development of PTC596, a Novel Small-Molecule Tubulin-Binding Agent
por: Jernigan, Finith, et al.
Publicado: (2021)

Characterization of Novel α-Mangostin and Paeonol Derivatives With Cancer-Selective Cytotoxicity
por: Nunna, Suneetha, et al.
Publicado: (2022)

Novel and Highly Potent ATR Inhibitor M4344 Kills Cancer Cells With Replication Stress, and Enhances the Chemotherapeutic Activity of Widely Used DNA Damaging Agents
por: Jo, Ukhyun, et al.
Publicado: (2021)

Anti-apoptotic MCL1 Protein Represents Critical Survival Molecule for Most Burkitt Lymphomas and BCL2-negative Diffuse Large B-cell Lymphomas
por: Klanova, Magdalena, et al.
Publicado: (2022)

Selectively Targeting Tumor Hypoxia With the Hypoxia-Activated Prodrug CP-506
por: van der Wiel, Alexander M.A., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_oi2kpn9n5c1db5ff5t5147db5c